Click to submit your search!

Prescribing Information | Important Safety Information | Our Advisory Board | For Health Care Professionals | Glossary

E-mail a Friend | | Print This Page

•  
• Rethink UC Remission
• Taking Lialda
• Living with UC
• Ulcerative Colitis Basics
• Connect 2 More Support Program

» Home » Taking Lialda » How Lialda Is Designed to Work

How Lialda^® Is Designed to Work

See what happens inside the colon during an ulcerative colitis (UC) flare. "The Inside Story" video lets you take a look at ulcerative colitis from the inside so you can see what inflammation looks like and watch how Lialda is designed to work.

You'll learn why inflammation of the lining of the colon leads to symptoms such as diarrhea, rectal bleeding, urgency, and abdominal pain. And you'll get a better understanding of how Lialda with MMX^® Technology delivers medicine where it's needed most to help control UC symptoms and enable healing by reducing inflammation.

Lialda is approved for the induction of remission in patients with active, mild to moderate ulcerative colitis. The safety and effectiveness of Lialda have been established in 2 eight-week clinical trials.

Important Safety Information

You should not take Lialda if you are allergic to salicylates (including mesalamine or aspirin) or to any of the ingredients of Lialda. Tell your doctor if you have a stomach blockage or are allergic to sulfasalazine. Mesalamine has been associated with a syndrome that may be difficult to distinguish from an ulcerative colitis flare-up. If you experience cramping, abdominal pain, bloody diarrhea, fever, headache or rash, talk to your doctor immediately. Some patients taking mesalamine have reported heart-related hypersensitivity reactions, such as inflammation of the heart muscle and inflammation of the lining of the heart. Tell your doctor if you have problems with your liver or kidneys.

In worldwide clinical trials, Lialda was generally well tolerated. The most common adverse events were headache and flatulence. As with other medications, some serious side effects may occur. Less than 1% of patients experienced inflammation of the pancreas, which led to discontinuation of therapy with Lialda.

Please see Lialda Full Prescribing Information

©2009 LIA-00772 09/09
Lialda^® is a registered trademark of Shire LLC. MMX^® is a registered trademark owned by Cosmo Technologies Ltd, Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA.
© 2009 Shire US Inc., Wayne, PA 19087 (800) 828-2088. All rights reserved.

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.